Title
Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1.

Permalink
https://escholarship.org/uc/item/23f3211z

Authors
Khamaiakwin, Wannisa
Shimizu, Saki
Kamata, Masakazu
et al.

Publication Date
2018-06-01

DOI
10.1016/j.omtm.2017.11.008

Peer reviewed
Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1

Wannisa Khamaiakwinn, Saki Shimizu, Masakazu Kamata, Ruth Cortado, Yujin Jung, Jennifer Lam, Jing Wen, Patrick Kim, Yiming Xie, Sanggu Kim, Hubert Arokium, Angela P. Presson, Irvin S.Y. Chen, and Dong Sung An

INTRODUCTION

Investigations of anti-HIV-1 human hematopoietic stem/progenitor cell (HSPC)-based gene therapy have been performed by HIV-1 challenge after the engraftment of genetically modified HSPCs in humanized mouse models. However, the clinical application of gene therapy is to treat HIV-1-infected patients. Here, we developed a new method to investigate an anti-HIV-1 HSPC-based gene therapy in humanized mice previously infected with HIV-1. First, humanized mice were infected with HIV-1. When plasma viremia reached >10^7 copies/mL 3 weeks after HIV-1 infection, the mice were infected with HIV-1. Anti-HIV-1 gene-modified HSPCs successfully reconstituted peripheral blood and lymphoid tissues in HIV-1 previously infected humanized mice. This new method will be useful for investigations of anti-HIV-1 gene therapy when testing in a more clinically relevant experimental setting.

Various anti-HIV-1 genes have been developed to genetically protect human CD34+ HSPCs and their progenies. Previously, in vivo investigations of these anti-HIV-1 genes have been performed by viral challenge after transplantation of anti-HIV-1 gene-modified HSPCs in immunodeficiency mice. The experimental design allowed us to examine the engraftment of anti-HIV-1 gene-modified HSPCs without confounding HIV-1 pathogenic effects. Subsequently, the mice are challenged with HIV-1 to examine the protection of anti-HIV-1 gene-modified immune cells. Using this protocol, we demonstrated that human CD34+ HSPCs transduced by an anti-HIV-1 lentiviral vector expressing dual short hairpin RNAs (shRNAs) targeting CCR5 and HIV-1 long terminal repeat (LTR) successfully reconstituted anti-HIV-1 vector-modified multi-lineage hematopoietic cells in humanized BM, liver, and thymus (BLT)-transplanted mice; we also demonstrated the selective advantage of the anti-HIV-1 dual shRNA gene expressing CD4+ T lymphocytes after an HIV-1 challenge in the reconstituted mice. However, it is unknown whether the anti-HIV-1 gene-modified HSPCs can engraft, differentiate into mature hematopoietic cells, and be protected in humanized mice previously infected with HIV-1.

In this report, our primary goal was to establish a new method to examine an anti-HIV-1 HSPC-based gene therapy strategy in humanized mice previously infected with HIV-1. First, we prepared humanized mice by transplanting human fetal liver-derived CD34+ HSPCs into irradiated neonatal NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Humanized mice were subsequently infected with HIV-1. When plasma viremia reached >10^7 copies/mL, HIV-1-infected humanized mice were preconditioned with busulfan and transplanted.
with anti-HIV-1 gene-modified, human fetal liver-derived CD34+ HSPCs and human thymus tissue from the same donor to repopulate HIV-1-resistant, gene-modified immune cells in lymphoid organs in the HIV-1 previously infected humanized mice. Using this new experimental method, we evaluated the engraftment of the dual shRNAs, CCR5 (sh1005) and HIV-1 LTR (sh516), modified HSPCs, differentiation into mature hematopoietic cells, tissue reconstitution, and the selective advantage of CD4+ T lymphocytes in the HIV-1 previously infected humanized mice.

RESULTS

Preparation of HIV-1-Infected Humanized NSG Mice
We investigated a new method to test anti-HIV-1 HSPC-based gene therapy in humanized mice previously infected with HIV-1 (Figure 1). To reconstitute HIV-1 target human hematopoietic cells, neonatal NSG mice (1–3 days old) were irradiated at 125 cGy and transplanted with human fetal liver-derived CD34+ HSPCs from 5 donors (0.5 × 10^5–1.0 × 10^5 cells per mouse) by an intrahepatic injection. Human multi-lineage hematopoietic cells (CD45+, CD3+ T lymphocyte and CD19+ B lymphocyte, and CD4+ CD8+ T lymphocyte populations) were reconstituted in peripheral blood 10 weeks after CD34+ HSPC transplant, determined by monoclonal antibody staining and multi-color flow cytometric analysis (Figure 2). Humanized mice were divided to create 2 groups with similar percentage levels of CD45+, CD3+ CD19+, and CD4+ CD8+ cell reconstitution and equally divided among donors (Figure 2, lower panels). Group 1 mice (n = 11) were infected with CCR5-tropic HIV-1NFNSX (200 ng of p24 Gag) intravenously via retro-orbital vein plexus 11 weeks after CD34+ HSPC transplant. Group 2 mice (n = 12) were used as a non-HIV-1-infected control. Plasma viral load reached an average of 1.25 × 10^7 copies/mL ± 1.48 × 10^7 SD 3 weeks after HIV-1 injection.

Transplantation of Anti-HIV-1 Gene-Vector-Transduced HSPCs in HIV-1 Previously Infected Humanized Mice
HIV-1-infected (n = 11) and HIV-1-uninfected (n = 12) humanized mice were myeloblated by an intraperitoneal injection of busulfan (35 mg/kg) 3 weeks after HIV-1 infection. To avoid potential problems caused by human leukocyte antigen (HLA) mismatch, cryopreserved, human fetal liver-derived CD34+ HSPCs from the same donors were thawed and transduced with the anti-HIV-1 dual shRNA sh1005/sh516 vector (EGFP marked) or the
After vector transduction overnight, vector-transduced cells (0.5 x 10^6 cells) were mixed at a 1:1 ratio and transplanted intravenously via retro-orbital vein plexus, along with a cryopreserved, donor-matched human thymus tissue piece under the kidney capsule to create a human thymus implant, as previously described.15,28,34,39,40 The efficiencies of vector transduction in CD34+ HSPCs (n = 5) were determined by %EGFP expression at 72.92 ± 10.84 (% ± SD) and by %mCherry expression at 73.28 ± 18.98 (% ± SD) in an aliquot culture with cytokine stimulation (stem cell factor [SCF], interleukin-3 [IL-3], and IL-6 at 50 ng/mL each) 3 days after vector transduction.

Repopulation of Anti-HIV-1 Gene-Modified Human Hematopoietic Cells in HIV-1 Previously Infected Humanized Mice

Multi-lineage hematopoietic cell repopulation of EGFP+ or mCherry+ vector-modified cells was initially evaluated in peripheral blood 6 weeks after vector-modified CD34+ HSPC transplant (Figure 3). EGFP+ or mCherry+ expressing cells were identified in human CD45+ hematopoietic cells, CD3+ T lymphocytes and CD19+ B lymphocytes, and CD4+ T lymphocytes and CD8+ T lymphocytes in peripheral blood in both HIV-1-infected and non-HIV-1-infected humanized mice. There was statistically significant difference between %EGFP and %mCherry in human CD4+ T lymphocytes in HIV-1 infected humanized mice (p < 0.05), but not in other lineages at this earliest time point (p > 0.05, paired Student’s t test).

Selective Advantage of Anti-HIV-1 Gene Vector-Modified Human Hematopoietic Cells in HIV-1 Pre-infected Humanized Mice

Kinetics of %EGFP and %mCherry expressing CD4+ T lymphocytes were monitored in peripheral blood from 6 to 10 weeks after vector-modified CD34+ HSPC transplant. %EGFP increased more than %mCherry in CD4+ T lymphocytes in the HIV-1 previously infected humanized mice (p < 0.0001, group-time interaction from a linear mixed-effects model) (Figure 4B). There were no significant differences in the kinetics of %EGFP and %mCherry expression in CD4+ T lymphocytes in HIV-1-uninfected humanized mice (Figure 4A) and CD8+ T lymphocytes in both uninfected and HIV-1 pre-infected humanized mice (p > 0.05, group-time interaction from a linear mixed-effects model) (Figures 4C and 4D). We then analyzed tissue repopulation 12 weeks after vector-modified CD34+ HSPC transplant. The mean %EGFP was higher than the mean %mCherry in CD4+ T lymphocytes in BM, lung, and gut in the HIV-1 previously infected humanized mice (Figure 5; Figure S1), suggesting that anti-HIV-1 dual sh1005/sh516 vector-modified CD4+ T lymphocytes were positively selected by HIV-1-induced selective pressure in HIV-1 previously infected humanized mice. Viral load, however, was maintained in all HIV-1 previously infected humanized mice 12 weeks after anti-HIV-1 gene vector-modified CD34+ HSPC transplant (2.35 ± 4.10 x 10^7 copies/mL ± SD). Because each animal was reconstituted with not only EGFP+ anti-HIV-1 gene vector-modified cells, but also cells marked with mCherry no-shRNA control vector and unmodified cells, the maintenance of viral load was expected. Altogether, these results demonstrated anti-HIV-1 dual sh1005/sh516 vector-modified HSPCs were able to engraft and...
differentiate into mature lymphocytes in the presence of HIV-1 infection. The anti-HIV-1 dual sh1005/sh516 vector-modified CD4+ T lymphocytes were positively selected over unprotected cells in the HIV-1 previously infected humanized mice.

**CCR5 Downregulation**

The level of CCR5 expression was compared in EGFP+ and mCherry+ CD4+ T lymphocytes in tissues 12 weeks after vector-modified CD34+ HSPC transplant. The level of CCR5 expression in the EGFP+ CD4+ T lymphocytes was reduced relative to that of the control mCherry+ CD4+ T lymphocytes in tissues in HIV-1-uninfected humanized mice (Figure 6; Figure S2), similar to our previously published results. In humanized mice previously infected with HIV-1, CCR5 expression was reduced in EGFP+ CD4+ T lymphocytes. In addition, CCR5 expression was reduced in control mCherry+ CD4+ T lymphocytes. This could be due to HIV-1-mediated depletion of unprotected mCherry+ CD4+ T lymphocytes in HIV-1 previously infected humanized mice. Therefore, we did not observe a difference in relative CCR5 expression levels in EGFP+ and mCherry+ CD4+ T lymphocytes.

**DISCUSSION**

In this study, we developed a new method to test an anti-HIV-1 HSPC-based gene therapy in HIV-1 previously infected humanized mice. The practical clinical application of anti-HIV-1 HSPC-based gene therapy is to treat HIV-1-infected patients. Thus, it is important to examine anti-HIV-1 HSPC-based gene therapy strategies in animals already infected with HIV-1.

In our new method, we first infected humanized mice with HIV-1. After the establishment HIV-1 infection, determined by viremia, HIV-1-infected humanized mice were treated with busulfan for myeloablative conditioning and transplanted with anti-HIV-1 vector-modified fetal liver CD34+ HSPCs 3 weeks after HIV-1 challenge with human thymus tissue transplant under the kidney capsule. Both %EGFP+ and %mCherry+ expression were analyzed in human CD45+ hematopoietic cells, CD3+ T lymphocytes, and CD19+ B lymphocytes in peripheral blood 6 weeks after vector-modified CD34+ HSPC transplant by flow cytometric analysis. A representative flow plot is shown on the top of each graph. The graph shows %EGFP+ (closed) and %mCherry+ (open) cells from all mice. The horizontal bars represent the mean. The vertical bars represent the SE. *p < 0.05. NS, not significant.
gene-modified HSPCs. Using this protocol, we were able to evaluate the engraftment of anti-HIV-1 gene vector-modified HSPCs, differentiation, tissue reconstitution, and selective advantage of anti-HIV-1 gene-modified cells in HIV-1 previously infected humanized mice. This new in vivo experimental method is more clinically relevant than previous experimental procedures in which anti-HIV-1 gene-modified HSPCs are first transplanted in uninfected humanized mice and subsequently challenged with HIV-1 to assess the efficacy of anti-HIV-1 reagents.

Human HSPCs were genetically engineered with the lentiviral vector expressing two anti-HIV-1 shRNAs: sh1005 directed to CCR5 and sh516 directed to HIV-1 LTR R region sequences.15 The repopulation, CCR5 downregulation, and selective advantage of anti-HIV-1 gene-modified cells in humanized mice already infected with HIV-1 were comparable to our previously published post-infection results.15,28,34 Our new results demonstrated that the anti-HIV-1 dual sh1005/sh516 vector-modified HSPCs successfully engrafted and differentiated into the HIV-1-resistant progeny CD4+ T cells and then selected from HIV-1-induced T cell loss in humanized mice already infected with HIV-1. To our knowledge, this is the first study to present successful engraftment of anti-HIV-1 gene-modified human HSPCs in HIV-1-infected humanized mice.

Accumulated evidence suggests that the current anti-retroviral drug therapy cannot provide a cure for AIDS.45–47 Thus far, the first and only clinical cure of HIV/AIDS was achieved by transplants of CCR5Δ32/Δ32 homozygous HIV-1-resistant donor BM cells.8–11 However, wider clinical application of such a protocol is impractical due to scarcity of HLA-matched allogeneic CCR5Δ32/Δ32 homozygous BM donors.10,49 Autologous HSPC-based gene therapy can eliminate the need for finding HLA type-matched allogeneic CCR5Δ32/Δ32 homozygous BM donors. It has a potential to develop as a novel therapeutic strategy for an HIV-1 cure. To better evaluate the potential of anti-HIV-1 HSPC-based gene therapy strategies, it is desirable to examine in a clinically relevant setting. Our newly developed method to reconstitute HIV-1 already infected humanized mice with anti-HIV-1 gene-modified HSPCs will be a useful tool to investigate various anti-HIV-1 HSPC-based gene therapy strategies in vivo in an experimentally tractable, small animal model system.

MATERIALS AND METHODS

Human CD34+ HSPCs and Fetal Tissue

Human fetal thymuses and fetal livers were obtained from Advanced Bioscience Resources (ABR), FPA Women’s Health, and the UCLA
Center for AIDS Research (CFAR) Gene and Cellular Therapy Core. The UCLA institutional review board has determined that these tissues are not human subjects and do not require an institutional review board review, because fetal tissues were obtained without patient-identifying information from deceased fetuses. Written informed consent was obtained from patients for the use of tissues in research purposes. CD34+ HSPCs were isolated from fetal livers using anti-CD34+ magnetic bead-conjugated monoclonal antibodies (Miltenyi Biotec) and cryopreserved in Bambanker (Wako Chemical USA). Human thymus pieces from the same donor were cryopreserved in 10% DMSO (Sigma-Aldrich) in human AB serum and stored in liquid nitrogen, as previously published. They were thawed at 37°C in a water bath before use.

Humanized Mice
NSG mice were maintained at the UCLA CFAR Humanized Mouse Core laboratory in accordance with a protocol approved by the UCLA Animal Research Committee. All experiments conform to all relevant regulatory standards. Neonatal NSG mice (1–3 days old) were irradiated (125 cGy) and transplanted with human fetal liver CD34+ HSPCs (0.5 x 10^5–1.0 x 10^5 cells per mouse) by intrahepatic injection.

HIV-1 Infection
CCR5-tropic HIV-1 NFNSX stocks were prepared by a calcium phosphate plasmid DNA transfection method as previously described. Humanized NSG mice were injected with HIV-1 NFNSX (200 ng of p24 Gag) via the retro-orbital vein plexus using a 27-gauge needle.

Viral Load Assay
Levels of HIV-1 RNA in plasma of infected humanized mice were determined by RT-PCR assay. 100 μL of whole blood was harvested via the retro-orbital vein plexus 3 weeks after HIV-1 infection. Approximately 50 μL of plasma was separated from peripheral blood and stored at −80°C until use. Viral RNA was isolated with a QIAamp viral RNA mini kit (QIAGEN). The RNA was eluted in 25 μL of RNase-free water, and 5 μL of elution was applied for qRT-PCR using an iScript One-step RT-PCR kit (Bio-Rad), with the following primers and probe specific to HIV-1 NFNSX gag region: primer sequence 1, 5'-CCCTACCAGCATTTCTGGACATAAG-3'; primer sequence 2, 5'-GCTTGCTCGGCTCTTAGAGTT-3'; and probe 5'-FAM-ACAAGGACCAAAGGAACCCTT-BHQ1-3'. With these primers and probe, HIV-1 RNA can be quantitatively detected from 10^3 to 10^8 copies/mL.

Lentiviral Vector Production
Vesicular stomatitis virus G protein (VSVG)-pseudotyped lentiviral vector stocks were produced by calcium phosphate-mediated transient transfection of HEK293T cells, as previously described. Vector stocks were titered on HEK293T cells.
Figure 6. CCR5 Downregulation in Human CD4+ T Lymphocytes in Tissues

The level of CCR5 expression was compared in EGFP+ and mCherry+ human CD4+ T lymphocytes in multiple lymphoid tissues 12 weeks after vector-modified CD34+ HSPC transplant. (A) Representative data showing CCR5 downregulation in bone marrow (BM), lung, gut, spleen, and human thymus implant (Hu thymus) under the kidney capsule from the mock (HIV-1-uninfected) humanized mouse (upper panels) and the HIV-1 previously infected (HIV-1-infected) humanized mouse (lower panels). (B) CCR5 expression was compared in EGFP+ and mCherry+ CD4+ T lymphocytes from all mice. We normalized the CCR5 expression level using the mean CCR5 expression in mCherry+ cells from peripheral blood (PB) as 1, using the same method as in our previous publication.28 The horizontal bars represent the mean. The vertical bars represent the SE. *p < 0.05. **p < 0.01. NS, not significant.
based on EGFP or mCherry expression analyzed by flow cytometric analysis.

**Lentiviral Vector Transduction**

The cryopreserved, fetal liver-derived CD34+ HSPCs (0.5 × 10⁶) were thawed and seeded into 20 µg/mL RetroNectin (Clontech Laboratories)-coated plates with 2% BSA (Sigma-Aldrich) in Yssel’s medium (GEMINI Bio Products). After 1 h of incubation, cells were transduced with either anti-HIV-1 dual sh1005/sh516 (MOI = 3) or no-shRNA control lentiviral vector (MOI = 1) overnight without cytokine stimulations to achieve the similar transduction efficiency measured by %EGFP or %mCherry expression, respectively. An aliquot of each transduced CD34+ HSPC was cultured in RPMI 1640 (Gibco) with 10% fetal bovine serum (HyClone), supplemented with cytokine stimulations (SCF, IL-3, and IL-6; all three from PeproTech) at a concentration of 50 ng/mL for 3 days. The efficiencies of vector transfection were evaluated by flow cytometry (Fortessa flow cytometers, BD Biosciences). After transduction, vector-transduced CD34+ HSPCs were mixed at a 1:1 ratio for transplantation into mice.

**Transplantation of Anti-HIV-1 Gene-Modified CD34+ HSPCs and Thymus Implantation in Humanized Mice Already Infected with HIV-1**

HIV-1-infected and mock-infected humanized NSG mice were myeloablated by an injection of busulfan (35 mg/kg) (Sigma-Aldrich) in the peritoneal cavity one day before transplant. An equal mixture of vector-transduced CD34+ HSPCs (0.5 × 10⁶) was solidified with 5 µL of Matrigel (BD Biosciences). CD34+ cells (4.5 × 10⁵) were also mixed in the Matrigel as feeder cells. The Matrigel-solidified cell mix was implanted with a piece of thymus under the kidney capsule. On the same day, mice were injected with the vector-transduced human CD34+ HSPCs (0.5 × 10⁶) using a 27-gauge needle through the retro-orbital vein plexus.

**Flow Cytometry**

Isolation of peripheral blood mononuclear cells (PBMCs) and cells from the BM, lung, gut, spleen, and human thymus implant were described previously. Peripheral blood- and tissue-derived mononuclear cells were stained with monoclonal antibodies to human CD45-εFluor 450 (HI30, eBioscience), CD3-APC H7 (SK7, Pharmingen), CD4-APC (OKT4, eBioscience), and CD8-PerCP Cy5.5 (SK1, BioLegend), CD19-Brilliant Violet 605 (HB19, BD Horizon), and CCR5-PECy7 (2D7, Pharmingen). Red blood cells were lysed with red cell lysis buffer after cell surface marker staining. Stained cells were fixed with 1% formaldehyde in PBS and examined with Fortessa flow cytometers (BD Biosciences). The data were analyzed by FlowJo v.10 (Tree Star) software.

**Statistical Analysis**

A linear mixed-effects model was used to evaluate differences in log-transformed EGFP or mCherry marker intensity levels by HIV status at (1) baseline and (2) over time in Figure 4. The difference between groups and time was evaluated using a group-time interaction, and the p value for this interaction was calculated using a likelihood ratio test comparing the models with and without the interaction term. Given that there were three time points, time was modeled as a categorical variable. A compound symmetry correlation structure was used for all models. The paired Student’s t test was used for other statistical analysis. Statistical significance was evaluated as *p < 0.05. We indicate other significance levels as follows: **p < 0.01, ***p < 0.001, and ****p < 0.0001. Statistical analyses were performed using GraphPad Prism.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes two figures and can be found with this article online at https://doi.org/10.1016/j.omtm.2017.11.008.

**AUTHOR CONTRIBUTIONS**

D.S.A., S.S., and I.S.Y.C. designed experiments. W.K., S.S., R.C., J.W., P.K., Y.X., Y.J., J.L., S.K., H.A., A.P.P., and M.K. performed experiments and analyzed data. D.S.A., S.S., and W.K. wrote the paper.

**CONFLICTS OF INTEREST**

The authors declare no competing conflicts of interests.

**ACKNOWLEDGMENTS**

We thank CTSI statistical core for the statistical analysis and Isabel Mak for critical reading and edits of our manuscript. This research was supported by NIAID 1R01AI100652-01A1. NIAID 1U19AI117941-01, the UCLA AIDS Institute, the UCLA Center for AIDS Research NIH/NIAID AI028697, and the California Institute for Regenerative Medicine (DR1-01431 to I.S.Y.C.). We thank Dr. Rachel Steward and the FPA Women’s Health and the UCLA AIDS Institute/CFAR Virology Core/Gene and Cell Therapy Core/Humanized Mouse Core for providing human cells and tissues and human-ized mice services.

**REFERENCES**

1. Kiem, H.P., Jerome, K.R., Deeks, S.G., and McCune, J.M. (2012). Hematopoietic-stem cell-based gene therapy for HIV disease. Cell Stem Cell 10, 137–147.

2. Zhen, A., and Kitchen, S. (2013). Stem-cell-based gene therapy for HIV infection. Viruses 6, 1–12.

3. van Griensven, J., De Clercq, E., and Debyser, Z. (2005). Hematopoietic stem cell-based gene therapy against HIV infection: promises and caveats. AIDS Rev. 7, 44–55.

4. Kitchen, S.G., Shimizu, S., and An, D.S. (2011). Stem cell-based anti-HIV gene therapy. Virology 411, 260–272.

5. Pernet, O., Yadav, S.S., and An, D.S. (2016). Stem cell-based therapies for HIV/AIDS. Adv. Drug Deliv. Rev. 103, 187–201.

6. Johnston, R. (2016). Gene therapy to cure HIV: where to from here? AIDS Patient Care STDS 30, 531–533.

7. Hütter, G. (2016). Stem cell transplantation in strategies for curing HIV/AIDS. AIDS Res. Ther. 13, 31.

8. Hütter, G., Nowak, D., Mousnier, M., Ganepola, S., Müsing, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009). Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692–698.

9. Allers, K., Hütter, G., Hofmann, J., Loddenkemper, C., Rieger, K., Thiel, E., and Schneider, T. (2011). Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood 117, 2791–2799.

10. Symons, J., Vanderkerckhove, L., Hütter, G., Wensing, A.M., van Ham, P.M., Deeks, S.G., and Nijhuis, M. (2014). Dependence on the CCR5 coreceptor for viral
replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient. Clin. Infect. Dis. 59, 596–600.

11. Brown, T.R. (2015). I am the Berlin patient: a personal reflection. AIDS Res. Hum. Retroviruses 31, 1–3.

12. Li, M.J., Kim, J., Li, S., Ziaia, J., Yee, J.K., Anderson, J., Akkina, R., and Rossi, J.J. (2005). Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900–909.

13. An, D.S., Donahue, R.E., Kamata, M., Poon, B., Metzger, M., Mao, S.H., Bonifacino, A., Krouse, A.E., Darlix, J.L., Baltimore, D., et al. (2007). Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc. Natl. Acad. Sci. USA 104, 13110–13115.

14. Liang, M., Kamata, M., Chen, K.N., Pariente, N., An, D.S., and Chen, I.S. (2010). Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. J. Gene Med. 12, 255–265.

15. Ringpis, G.E., Shimizu, S., Arokiusam, H., Camba-Colón, J., Carroll, M.V., Cortado, R., Xie, Y., Kim, P.Y., Sahayakan, A., Lowe, E.L., et al. (2012). Engineering HIV-1-resistant T-cells from short hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PLoS ONE 7, e53492.

16. Wolstein, O., Boyd, M., Millington, M., Impey, H., Boyer, J., Howe, A., Delebecque, F., Cornetta, K., Rothe, M., Baum, C., et al. (2014). Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol. Ther. Methods Clin. Dev. 1, 11.

17. Li, L., Krymskaya, L., Wang, J., Henley, J., Rao, A., Cao, L.F., Tran, C.A., Torres-Coronado, M., Gardner, A., Gonzalez, N., et al. (2013). Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol. Ther. 21, 1259–1269.

18. Mandal, P.K., Ferreira, L.M., Reiss, T.N., Bruggeman, C.L., Friesen, M., Vrbacan, V., Garrison, B.S., Stortchevoy, A., Avery, D., et al. (2014). Efficient ablation of genes in human hematopoietic stem and effectors cells using CRISPR/Cas9. Cell Stem Cell 15, 643–652.

19. Zahn, R.C., Hermann, F.G., Kim, E.Y., Ziegler, P., Hackmann, K., et al. (2013). Highly significant reduction of HIV-1 replication explains the lack of rebound of CXCR4-predicted HIV variants in the Berlin patient: a personal reflection. AIDS Res. Hum. Retroviruses 31, 1–3.

20. Li, M.J., Kim, J., Li, S., Ziaia, J., Yee, J.K., Anderson, J., Akkina, R., and Rossi, J.J. (2005). Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900–909.

21. An, D.S., Donahue, R.E., Kamata, M., Poon, B., Metzger, M., Mao, S.H., Bonifacino, A., Krouse, A.E., Darlix, J.L., Baltimore, D., et al. (2007). Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc. Natl. Acad. Sci. USA 104, 13110–13115.
45. Archin, N.M., Sung, J.M., Garrido, C., Soriano-Sarabia, N., and Margolis, D.M. (2014). Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat. Rev. Microbiol. 12, 750–764.

46. Kelley, C.F., Kitchen, C.M., Hunt, P.W., Rodriguez, B., Hecht, F.M., Kitahata, M., Crane, H.M., Willig, J., Mugavero, M., Saag, M., et al. (2009). Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin. Infect. Dis. 48, 787–794.

47. Castagna, A., Ferrara, M., Galli, L., Comi, L., Serrantino, G., Cenderello, G., Zaccarelli, M., Focà, E., Roncadori, A., and Lazzarin, A.; PRESTIGIO Study Group (2017). Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. J. Antimicrob. Chemother., Published online October 4, 2017. https://doi.org/10.1093/jac/dkx371.

48. Hütter, G., and Thiel, E. (2011). Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS 25, 273–274.

49. Martinson, J.J., Chapman, N.H., Rees, D.C., Liu, Y.T., and Clegg, J.B. (1997). Global distribution of the CCR5 gene 32-basepair deletion. Nat. Genet. 16, 100–103.